# Belimumab With Rituximab for Primary Membranous Nephropathy

> **NCT03949855** · PHASE2 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 58 (estimated)

## Conditions studied

- Membranous Nephropathy
- Nephrotic Syndrome

## Interventions

- **DRUG:** Belimumab
- **DRUG:** Placebo for Belimumab
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03949855
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-03-06
- **Primary completion:** 2029-03-01
- **Final completion:** 2030-03-01
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03949855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03949855, "Belimumab With Rituximab for Primary Membranous Nephropathy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03949855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*